DIADEMA PARTNERS LP
Q3 2026 Form 13-F
MORRISTOWN, DELAWARE
CIK 0002026172
· CRD 331527
· SEC-registered investment adviser
$780.5M Reported Value Total
DIADEMA PARTNERS LP reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $397,900,939, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $337.6M gross asset value
Hedge Fund: $337.6M
Source: Form ADV filed 2026-03-20
Reported value
$780.5M
Quarter over quarter
-2.6%
Holdings
81
Top-10 concentration
38.4%
Filing Structure
Key People
Form ADV owners & control persons
Timothy Beau Bassett
CHIEF INVESTMENT OFFICER, LIMITED PARTNER
Zachary Kayn Canonico
CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $780.5M |
| Positions | 81 |
| Change in reported value | -1.4% |
| New positions | 36 |
| Exited positions | 31 |
| Position turnover | 59.8% |
| Top-10 concentration | 38.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
81 | $780.5M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
77 | $791.3M |
|
Q1 2026 13F
Filed May 15, 2026
|
86 | $587.7M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
73 | $580.5M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
59 | $391.0M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
46 | $328.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
43 | $383.3M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
54 | $233.1M |
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | VKTX P VIKING THERAPEUTICS INC | $44.4M | 5.69% |
| 2 | BMY C BRISTOL-MYERS SQUIBB CO | $37.4M | 4.8% |
| 3 | VKTX C VIKING THERAPEUTICS INC | $37.1M | 4.76% |
| 4 | VKTX VIKING THERAPEUTICS INC | $32.6M | 4.18% |
| 5 | KOD P KODIAK SCIENCES INC | $28.2M | 3.61% |
| 6 | UTHR C UNITED THERAPEUTICS CORP DEL | $25.7M | 3.3% |
| 7 | UTHR UNITED THERAPEUTICS CORP DEL | $25.0M | 3.21% |
| 8 | BNTX C BIONTECH SE | $24.6M | 3.15% |
| 9 | KOD C KODIAK SCIENCES INC | $23.9M | 3.06% |
| 10 | BMY P BRISTOL-MYERS SQUIBB CO | $20.6M | 2.64% |
| 11 | COGT COGENT BIOSCIENCES INC | $20.6M | 2.63% |
| 12 | GMAB C GENMAB A/S | $18.5M | 2.37% |
| 13 | KYMR C KYMERA THERAPEUTICS INC | $18.0M | 2.3% |
| 14 | ABVX ABIVAX SA | $17.7M | 2.27% |
| 15 | BBIO 1.75 03/01/31 BRIDGEBIO PHARMA INC | $16.5M | 2.11% |
| 16 | SMMT C SUMMIT THERAPEUTICS INC | $16.2M | 2.08% |
| 17 | BMRN BIOMARIN PHARMACEUTICAL INC | $15.3M | 1.96% |
| 18 | RVMD REVOLUTION MEDICINES INC | $14.4M | 1.84% |
| 19 | NVS P NOVARTIS AG | $14.3M | 1.83% |
| 20 | VKTX VIKING THERAPEUTICS INC | $14.1M | 1.81% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.